United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics Corporation will release its first quarter 2022 financial results on May 4, 2022, before market open. A public webcast will be held on the same day at 9:00 a.m. ET, accessible via their website. The company, recognized as the first publicly traded biotech under the public benefit corporation model, focuses on curing pulmonary arterial hypertension and expanding the availability of transplantable organs, boasting five FDA-approved medications. Forward-looking statements highlight ongoing clinical trials and risk factors, as outlined in SEC filings.

United Therapeutics announced positive results from the BREEZE study evaluating Tyvaso DPI in patients with pulmonary arterial hypertension (PAH). The study showed safety in transitioning from Tyvaso to Tyvaso DPI with no serious adverse events. Improvements in six-minute walk distance by 11.5 meters and patient satisfaction were reported. Long-term safety data from an optional extension phase indicated continued efficacy. FDA action on the New Drug Application for Tyvaso DPI is anticipated by May 2022.

United Therapeutics Corporation (Nasdaq: UTHR) has announced that CFO James Edgemond will present a business overview during a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, from 9:20 a.m. to 9:50 a.m. EDT. The session will be available via a live webcast on the company's website, with an archived version accessible for 90 days post-event. United Therapeutics, a public benefit corporation, focuses on curing pulmonary arterial hypertension and has gained FDA approval for five medicines while aiming to innovate organ transplantation technologies.

United Therapeutics Corporation (Nasdaq: UTHR) announced that Michael Benkowitz, President and COO, will present an update during a fireside chat at the Cowen 42nd Annual Health Care Conference. The virtual session is scheduled for March 8, 2022, from 11:10 a.m. to 11:40 a.m. EST, accessible via webcast on United Therapeutics' website. The company aims to find a cure for pulmonary arterial hypertension and is notable for being the first public benefit corporation in biotech.

United Therapeutics (Nasdaq: UTHR) reported a significant revenue increase of 14% for the full year 2021, totaling $1,686 million, driven by strong patient growth in treprostinil-based therapies. The company aims to reach 6,000 patients using Tyvaso by the end of 2022. A major amendment to the Tyvaso DPI NDA has postponed the FDA decision to May 2022. The net income for 2021 was $475.8 million, down from $514.8 million in 2020. Non-GAAP earnings per diluted share increased to $15.26 from $14.46 in the previous year.

United Therapeutics Corporation (Nasdaq: UTHR) will report its fourth quarter and full year 2021 financial results on February 24, 2022, before market opening. A public webcast will take place at 9:00 a.m. ET on the same day. The company emphasizes its commitment to developing therapies for pulmonary arterial hypertension and expanding organ availability. As a public benefit corporation, it aims to balance patient and shareholder interests while promoting sustainability.

Forward-looking statements include anticipated clinical developments, subject to risks and uncertainties.

United Therapeutics (Nasdaq: UTHR) announced significant advancements in xenotransplantation with the world's first genetically-modified heart transplant (UHeart™) reaching a two-week milestone, showcasing normal organ function. Additionally, the UKidney™ procedure's data was published in the American Journal of Transplantation, marking a first in peer-reviewed studies. The UThymoKidney™ was noted for its historic preclinical study, furthering the quest for sustainable organ supply. These innovations reinforce United Therapeutics' commitment to transforming organ transplantation and improving patient outcomes.

United Therapeutics Corporation (Nasdaq: UTHR) announced that Martine Rothblatt, Ph.D., and Michael Benkowitz will engage in a fireside chat hosted by J.P. Morgan's biotech analyst, Jessica Fye. This virtual event is scheduled for January 6, 2022, from 8:00 a.m. to 8:45 a.m. EST, featuring updates on the company’s mission and business. Access will be through a live webcast, with an archived version available after the session. The company continues to pioneer treatments for pulmonary arterial hypertension and aims to expand organ transplant availability.